Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Pentamidine for Prevention of Hypertrophic Scar Formation
NCT03403621Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Mar 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Hypertrophic Scar (HS) comparing Topical Pentamidine Isethionate with Placebo Control (2 arms). Primary endpoint: Serious Adverse Events. Started Mar 2018; status: terminated.
02
Drugs
pentamidine
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT03403621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403621.